DXCM · NASDAQ · Medical - Devices

Dexcom (DXCM)

Builds continuous glucose monitors for diabetes care and broader metabolic-health tracking.

$89.39
vs last close+0.22 (+0.25%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue9751,0359211,0049941,1141,0361,1571,2091,2601,1921,308
Cost of revenue352378359378400458447468478467442478
Gross profit623657562627594656589689731793750830
418440461469442467455476489470495512
Research & development131136142136135140145148158148145153
Selling, general & administrative286309319333306327310328331322350359
Other expenses0−50000000000
Operating income206217101158152189134213243323255318
35293130252221291101814−1
Interest income423436363230292833242017
Interest expense555555555433
Other non-operating income−40−34−36−35−30−27−25−33−115−22−17−2
Income before tax240246133188177211154241352341270318
Income tax expense120−10−14444360496169737068
Net income from continuing operations121256146144135152105180284267200249
Net income121256146144135152105180284267200249
EPS, basic$0.31$0.67$0.38$0.36$0.35$0.39$0.27$0.46$0.73$0.69$0.52$0.65
EPS, diluted$0.29$0.62$0.36$0.35$0.34$0.38$0.27$0.45$0.70$0.68$0.51$0.64
Weighted average shares, basic387384390399394399391392391387385384
Weighted average shares, diluted427416417417410407408408407399394392
EBITDA294304190245237274219309421410340389
Depreciation & amortization485353525558606364656768
EBIT245251137193182216159246357345273321